Medicine and Dentistry
Cutaneous Lymphoma
79%
Nodular Melanoma
77%
T-Cell Lymphoma
70%
Mycosis fungoides
68%
Disease
58%
Peripheral T-Cell Lymphoma
45%
T Cell
37%
Neoplasm
34%
Malignant Neoplasm
34%
B-Cell Lymphoma
31%
Vemurafenib
30%
Follicle
30%
Cutaneous T Cell Lymphoma
29%
Targeted Therapy
27%
Non-Hodgkin Lymphoma
26%
Skin Tumor
22%
Klatskin Tumor
22%
Cancer Staging
22%
Dermatology
22%
Brentuximab Vedotin
22%
Spindle Cell
22%
Drug Eruption
22%
Hepatosplenic T-Cell Lymphoma
22%
Maintenance Therapy
22%
Exanthem
22%
Metastatic Carcinoma
22%
Cardiovascular Disease
22%
Disease Exacerbation
22%
Cytokine
22%
Immunotherapy
22%
Anaplastic Large Cell Lymphoma
19%
Side Effect
18%
Treatment Interruption
17%
Progression Free Survival
16%
Cardiovascular System
16%
Virus Oncogene
15%
Papulopustular
15%
Sarcoma
15%
Skin Manifestation
13%
Gamma Delta T-Cell
12%
Overall Survival
12%
Cancer Immunotherapy
11%
Prognostic Factor
11%
TNM Staging System
11%
Skin Cancer
11%
Recurrent Disease
11%
Non Melanoma Skin Cancer
11%
Merkel Cell Carcinoma
11%
Mitosis Rate
11%
Soft Tissue Tumor
11%
Keyphrases
Advanced Melanoma
45%
Melanoma
45%
Mycosis Fungoides
45%
T-cell Lymphoma
45%
T Cells
28%
NCCN Guidelines
28%
Anaplastic Large Cell Lymphoma
25%
Overall Survival
22%
Tumor
22%
NRAS mutation
22%
Primary Cutaneous Follicle Center Lymphoma
22%
BRAF mutation
22%
Brentuximab Vedotin
22%
Conventional Interferon
22%
Adjuvant Melanoma
22%
Expression Level
22%
Investigator-initiated Studies
22%
Melanoma Patients
22%
Historical Precedents
22%
Multi-institution
22%
Cutaneous Drug Eruption
22%
Xerosis Cutis
22%
Skin Tumor
22%
Anti-cytotoxic
22%
Basal Cell Carcinoma
22%
Hepatosplenic T-cell Lymphoma
22%
Melanoma Treatment
22%
Collaborative Projects
22%
TRBC1
22%
Cardiovascular Disease
22%
Mutation Status
22%
Forodesine
22%
Chemotherapy
22%
Targeted Therapy
22%
CD30 Expression
22%
Targeted Treatment
22%
Tumor Staging
22%
Heterogeneous Groups
17%
Peripheral T-cell Lymphoma
17%
Ipilimumab
16%
Immune Response
15%
Cancer Immunotherapy
15%
Vismodegib
15%
Treatment Options
15%
Clinical Outcomes
14%
Cardiovascular Events
12%
Merkel Cell Carcinoma
11%
Viral Oncogenes
11%
Locoregional Recurrence
11%
New Treatment Options
11%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Rash
45%
Mycosis fungoides
45%
Malignant Neoplasm
39%
Neoplasm
37%
Overall Survival
34%
Side Effect
33%
Vemurafenib
30%
Chemotherapy
30%
Ipilimumab
28%
Syndrome
25%
Azacitidine
22%
Cutaneous T Cell Lymphoma
22%
Peginterferon
22%
Romidepsin
22%
Interferon
22%
Forodesine
22%
Cytokine
22%
Drug Eruption
22%
Brentuximab Vedotin
22%
Immunotherapy
22%
Basal Cell Carcinoma
22%
Disease
21%
Skin Manifestation
21%
Adverse Event
19%
Clinical Trial
18%
Progression Free Survival
16%
Chimeric Antigen Receptor
16%
Epidermal Growth Factor Receptor Kinase Inhibitor
15%
Mitogen Activated Protein Kinase Kinase Inhibitor
15%
Sarcoma
15%
Xerosis
15%
Hand Foot Syndrome
15%
Cytotoxic T Lymphocyte Antigen 4 Antibody
13%
Alopecia
12%
Vismodegib
11%
Tolerability
8%
Mitogen Activated Protein Kinase Inhibitor
7%
Biological Product
7%
Skin Toxicity
7%
Stomatitis
7%
Radiation Dermatitis
7%
Injury
7%
Nail Dystrophy
7%
Face Erythema
7%
Paronychia
7%
Phosphotransferase Inhibitor
7%
Extravasation
7%
Imatinib
7%
Tremelimumab
7%